- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01276990
Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers.
February 8, 2012 updated by: Boehringer Ingelheim
Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 ZW (Powder in Bottle Formulation) at 12.5 mg q24h, 12.5 mg q12h, 12.5 mg q8h, 25 mg q12h, 25 mg q8h, 50 mg q12h, 37.5 mg q8h and 50 mg q8h Dose Levels for 10 Days in Healthy Male Volunteers (Randomized, Double-blind Placebo-controlled Within Dose Groups)
To investigate the safety and pharmacokinetic of BI 224436 in healthy male volunteers following oral administration of repeated doses for 10 days within 8 dosing regimens.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion criteria:
- Healthy male according to the following criteria: based upon a complete medical history, including the physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), clinical laboratory tests.
- Age >=18 and <=50 years.
- Body Mass Index (BMI) >=18.5 and BMI <=32 kg/m2.
- Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation.
- Documented to be sterile; or, if can father a child, agree to abstain from sexual intercourse during and at least seven days following last study drug administration, or are willing to use condoms during the same period each time (Subject's female sexual partner(s) of child-bearing potential should be willing to use either ethinyl estradiol containing oral contraceptives or a reliable barrier method of contraception).
Exclusion criteria:
- Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance according to the opinion of the investigator.
- Any evidence of a clinically relevant concomitant disease.
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders.
- Surgery of the gastrointestinal tract that in the opinion of the investigator may affect the absorption.
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders.
- History of relevant orthostatic hypotension, fainting spells or blackouts.
- History or evidence of Human Immunodeficiency Virus or other chronic or relevant acute infections, including Hepatitis C Virus and Hepatitis B Virus infection.
- History of relevant allergy / hypersensitivity (including allergy to investigational medicinal product or its solvent).
- History of any familial skeletal muscle disorder, or history of Creatine Kinase (CK) elevation not due to strenuous physical activity or trauma.
- Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial.
- Use of drugs, including prescription and non-prescription drugs, and St. Johns Wort which might reasonably influence the results of the trial within 14 days prior to study drug administration or during the trial, or consumption of grapefruit, grapefruit juice, orange juice, Seville oranges, green tea, pineapple, pineapple juice, broccoli or red wine within 3 days prior study drug administration or during the trial.
- Participation in another trial with an investigational drug within one month prior to administration or during the trial.
- Current smoker (>10 cigarettes or >3 cigars or >3 pipes / day).
- Inability to refrain from smoking during the trial.
- Alcohol abuse (more than 30 g day).
- Drug abuse.
- Blood donation (more than 100 mL within four weeks prior to administration or during the trial).
- Physical activity in excess of usual activity of daily living (e.g., fitness physical exercise, physical labor) within 7 days prior to study drug administration until end of study visit.
- Any laboratory value outside the reference range that in the opinion of the investigator is of clinical relevance.
- A marked baseline prolongation of QT or corrected QT (QTc) intervals (e.g., repeated demonstration of a QTc interval >450 ms); or, other ECG abnormality of clinical significance.
- A history of additional risk factors for Torsades de points (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
- CK at screening =2x Upper Limit of Normal (ULN) (If CK is =2xULN and <5xULN one retest will be allowed to verify the result).
- CK at baseline (Day -1) >ULN (If CK is >ULN and <1.5xULN one retest will be allowed to verify the result).
- Thyroid - stimulating hormone outside normal reference range, or history of hypo-or hyperthyroidism.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Matching placebo in dosing regimen 1-8
|
Oral drinking solution
Oral drinking solution
|
Experimental: BI 224436 dosing regimen 1
Dosing regimen 1
|
Oral drinking solution
|
Experimental: BI 224436 dosing regimen 2
Dosing regimen 2
|
Oral drinking solution
|
Experimental: BI 224436 dosing regimen 3
Dosing regimen 3
|
Oral drinking solution
|
Experimental: BI 224436 dosing regimen 4
Dosing regimen 4
|
Oral drinking solution
|
Experimental: BI 224436 dosing regimen 5
Dosing regimen 5
|
Oral drinking solution
|
Experimental: BI 224436 dosing regimen 6
Dosing regimen 6
|
Oral drinking solution
|
Experimental: BI 224436 dosing regimen 7
Dosing regimen 7
|
Oral drinking solution
|
Experimental: BI 224436 dosing regimen 8
Dosing regimen 8
|
Oral drinking solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events
Time Frame: 1 month
|
1 month
|
Changes in blood pressure
Time Frame: 1 month
|
1 month
|
Changes in pulse rate
Time Frame: 1 month
|
1 month
|
Changes in 12-lead ECG
Time Frame: 1 month
|
1 month
|
Changes in clinical laboratory test parameters
Time Frame: 1 month
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax,ss (maximum measured concentration of the analyte in plasma at steady-state over a uniform dosing interval t)
Time Frame: 10 days
|
10 days
|
tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady-state)
Time Frame: 10 Days
|
10 Days
|
Cmin,ss (minimum concentration of the analyte in plasma at steady-state over a uniform dosing interval t)
Time Frame: 10 days
|
10 days
|
AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady-state over a uniform dosing interval t)
Time Frame: 13 days
|
13 days
|
t1/2,ss (terminal half-life of the analyte in plasma at steady-state)
Time Frame: 13 days
|
13 days
|
CL/F,ss (apparent clearance of the analyte in the plasma at steady-state following extravascular multiple dose administration)
Time Frame: 13 days
|
13 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2011
Primary Completion (Anticipated)
September 1, 2012
Study Registration Dates
First Submitted
January 13, 2011
First Submitted That Met QC Criteria
January 13, 2011
First Posted (Estimate)
January 14, 2011
Study Record Updates
Last Update Posted (Estimate)
February 9, 2012
Last Update Submitted That Met QC Criteria
February 8, 2012
Last Verified
February 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1277.2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV Infections | HIV SeronegativityUnited States, Puerto Rico
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
Clinical Trials on BI 224436
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimRecruitingMelanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)Netherlands
-
Boehringer IngelheimNot yet recruiting
-
Boehringer IngelheimWithdrawnAnal Canal Squamous Cell CarcinomaKorea, Republic of
-
Boehringer IngelheimRecruiting
-
Boehringer IngelheimTerminated
-
Boehringer IngelheimCompleted